Nominations Open for the Prestigious Tu Youyou Award 2024
MDPI is pleased to announce the opening of nominations for the 2024 Tu Youyou Award, a prestigious recognition established in honor of Professor Tu Youyou, Nobel Laureate, whose discovery has significantly altered the global fight against Malaria.
The Tu Youyou Award offers CHF 100,000
In 2015, Professor Tu Youyou was awarded the Nobel Prize in Physiology or Medicine for her discovery of artemisinin, significantly reducing mortality rates from malaria and shaping global health policies. Artemisinin-based combination therapies (ACTs) are now the standard treatment endorsed by the World Health Organization (WHO). This groundbreaking work has saved countless lives, especially in regions heavily burdened by Malaria.
To mark Professor Tu's 80th birthday in 2009, MDPI's journal Molecules issued a Special Issue focusing on her contributions to medical research. Recognizing her continuous contribution, MDPI created the Tu Youyou Award in 2016 to honor outstanding achievements in natural products and medicinal chemistry.
The deadline for nominations is 31 December 2024
The Tu Youyou Award offers CHF 100,000, split equally among winners. Nominations are open to scientists excelling in natural products and medicinal chemistry. Eligible nominators include academic institutes, universities, and societies. Nominations close on 31 December 2024, with winners announced on 30 April 2025.
MDPI encourages the academic community to nominate individuals who have demonstrated excellence and innovation akin to Professor Tu’s legacy. This award not only honors individual achievement but also encourages further scientific exploration and discovery in critical areas of medicine.
Stefan Tochev, CEO of MDPI, said, “This award truly embodies our deep commitment to groundbreaking research that drives societal progress and celebrates the legacy of one of the greatest medical innovators of our time.”
For more information, please visit MDPI’s official website or the dedicated Tu Youyou Award page.
About MDPI
MDPI is leading the transition to open science by making more research free and accessible to everyone. Over 3.5 million researchers have entrusted MDPI with publishing their scientific discoveries. MDPI’s editorial process is bolstered by a network of dedicated reviewers, a team of 6000 diligent, well-trained staff members, and an in-house article submission platform that was designed to ensure efficient processes within its 445 fully OA titles.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240705939770/en/
Contacts
Rui Duarte, MDPI PR Manager
+41764313242
publicrelations@mdpi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea24.4.2025 10:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high potent manufacturing suitable for antibody-drug conjugates (ADCs). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424617540/en/ PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea. Althea’s robust clinical- and commercial-stage services for injectable drug products augments PCI’s deep industry experience, aligning with the company’s global sterile fill-fini
Wolters Kluwer Launches CCH iFirm Personal Tax and CCH iFirm Accounts Production for U.K. Tax and Accounting Professionals24.4.2025 10:00:00 EEST | Press release
Wolters Kluwer Tax and Accounting (TAA) today announced the launch of CCH iFirm Personal Tax and CCH iFirm Accounts Production within its award-winning cloud-based practice management and compliance software platform CCH iFirm® for U.K. professionals. These enhancements deliver seamless, integrated platforms that enhance efficiency, reduce errors, ensure compliance and a more efficient workflow for tax and accounting professionals. Bas Kniphorst, Executive Vice President and Managing Director, Wolters Kluwer TAA Europe said: “These cloud solution modules represent a significant milestone in our commitment to innovation and quality. By providing cutting-edge tools that meet the evolving demands of the tax and accounting industry, we are strengthening our position as a leader in cloud accounting solutions. This not only enhances our product portfolio but also drives growth and reinforces our dedication to delivering exceptional value to our clients. We are confident these launches will e
Jeffrey Lawrence Appointed Chairman of Joe & the Juice24.4.2025 10:00:00 EEST | Press release
Joe & the Juice (“the Company”), an urban juice bar and coffee concept selling freshly prepared juices, coffee, sandwiches and more, today announced that Jeffrey Lawrence, a member of the Company’s Board of Directors since April 2024, has been appointed as Chairman of the Board. Thomas Nørøxe, Chief Executive Officer of Joe & the Juice, said, “Jeff’s elevation to Chairman of Joe & the Juice reflects how his active participation has made a material difference to the Company’s performance and strategy. Over the past year, Joe & the Juice has achieved continued impressive same store sales and revenue growth as we also opened our 400th unit globally. Unit economics remain incredibly strong and digital sales are now nearing 40%. Jeff’s experience will be vital as we continue to expand globally through both company-owned and franchise openings.” Jeffrey Lawrence commented, “Joe & the Juice continues to represent one of the most exciting and dynamic restaurant brands, with true global consume
Manhattan Associates Wins Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics24.4.2025 10:00:00 EEST | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced that it has received the 2025 Google Cloud Business Applications Partner of the Year Award for Supply Chain and Logistics. This prestigious award highlights Manhattan’s role as an innovator within the Google Cloud ecosystem, its commitment to driving customer success, and its pioneering application of Agentic AI and Generative AI (GenAI) within the Manhattan Active® Suite over the past year. “Google Cloud’s Partner Awards recognize partners who have created outsized value for customers through the delivery of innovative solutions and a high level of expertise,” said Kevin Ichhpurani, President, Global Partner Ecosystem, Google Cloud. "We're proud to announce Manhattan Associates as a 2025 Google Cloud Partner Award winner and celebrate their impact enabling customer success over the past year." “We are honored to be recognized as Google Cloud’s 2025 Business Applications Partner of the Year Award for Supply Chain and Logistics,”
Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research24.4.2025 10:00:00 EEST | Press release
Debiopharm Research & Manufacturing S.A. (Debiopharm, www.debiopharm.com), a Swiss-based global biopharmaceutical company aiming to cure cancer and infectious diseases, and Oncodesign Services (www.oncodesign-services.com), a leading CRO specialized in drug discovery and preclinical services, announce the execution of a license agreement for the use of the AbYlink™ technology for preclinical services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424538240/en/ AbYlink™ is a regio-selective bioconjugation technology ideally suited for preparing conjugates for use in therapeutic and non-invasive diagnostic applications. Oncodesign Services will use this cutting-edge technology to prepare antibody chelator conjugates for use in preclinical studies to gain insights into the predictive effectiveness of novel treatment approaches in Molecular Radiotherapy, and particularly Radioimmunotherapy in the context of cancer. A joint p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom